Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-22584
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJuul, Sophie-
dc.contributor.authorSiddiqui, Faiza-
dc.contributor.authorBarbateskovic, Marija-
dc.contributor.authorJørgensen, Caroline Kamp-
dc.contributor.authorHengartner, Michael Pascal-
dc.contributor.authorKirsch, Irving-
dc.contributor.authorGluud, Christian-
dc.contributor.authorJakobsen, Janus Christian-
dc.date.accessioned2021-06-03T13:59:21Z-
dc.date.available2021-06-03T13:59:21Z-
dc.date.issued2021-
dc.identifier.issn2046-4053de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/22584-
dc.description.abstractBackground: Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders worldwide. Antidepressants are frequently used to treat major depressive disorder. It has been shown repeatedly that antidepressants seem to reduce depressive symptoms with a statistically significant effect, but the clinical importance of the effect sizes seems questionable. Both beneficial and harmful effects of antidepressants have not previously been sufficiently assessed. The main objective of this review will be to evaluate the beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder. Methods/design: A systematic review with meta-analysis will be reported as recommended by Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA), bias will be assessed with the Cochrane Risk of Bias tool-version 2 (ROB2), our eight-step procedure will be used to assess if the thresholds for clinical significance are crossed, Trial Sequential Analysis will be conducted to control for random errors, and the certainty of the evidence will be assessed with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. To identify relevant trials, we will search both for published and unpublished trials in major medical databases from their inception to the present. Clinical study reports will be obtained from regulatory authorities and pharmaceutical companies. Two review authors will independently screen the results of the literature searches, extract data, and perform risk of bias assessment. We will include any published or unpublished randomised clinical trial comparing one or more antidepressants with placebo, ‘active placebo’, or no intervention for adults with major depressive disorder. The following active agents will be included: agomelatine, amineptine, amitriptyline, bupropion, butriptyline, cianopramine, citalopram, clomipramine, dapoxetine, demexiptiline, desipramine, desvenlafaxine, dibenzepin, dosulepin, dothiepin, doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, imipramine, iprindole, levomilnacipran, lofepramine, maprotiline, melitracen, metapramine, milnacipran, mirtazapine, nefazodone, nortriptyline, noxiptiline, opipramol, paroxetine, protriptyline, quinupramine, reboxetine, sertraline, trazodone, tianeptine, trimipramine, venlafaxine, vilazodone, and vortioxetine. Primary outcomes will be depressive symptoms, serious adverse events, and quality of life. Secondary outcomes will be suicide or suicide attempt, suicidal ideation, and non-serious adverse events. Discussion: As antidepressants are commonly used to treat major depressive disorder in adults, a systematic review evaluating their beneficial and harmful effects is urgently needed. This review will inform best practice in treatment and clinical research of this highly prevalent and burdensome disorder.de_CH
dc.language.isoende_CH
dc.publisherBioMed Centralde_CH
dc.relation.ispartofSystematic Reviewsde_CH
dc.rightshttp://creativecommons.org/licenses/by/4.0/de_CH
dc.subject.ddc615: Pharmakologie und Therapeutikde_CH
dc.subject.ddc616.8: Neurologie und Krankheiten des Nervensystemsde_CH
dc.titleBeneficial and harmful effects of antidepressants versus placebo, ‘active placebo’, or no intervention for adults with major depressive disorder : a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analysesde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementAngewandte Psychologiede_CH
zhaw.organisationalunitPsychologisches Institut (PI)de_CH
dc.identifier.doi10.1186/s13643-021-01705-6de_CH
dc.identifier.doi10.21256/zhaw-22584-
dc.identifier.pmid34034811de_CH
zhaw.funding.euNode_CH
zhaw.issue154de_CH
zhaw.originated.zhawYesde_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume10de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.webfeedKlinische Psychologiede_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen Angewandte Psychologie

Files in This Item:
File Description SizeFormat 
2021_Juul-etal_Effects-of-antidepressants-vs-placebo.pdf674.34 kBAdobe PDFThumbnail
View/Open
Show simple item record
Juul, S., Siddiqui, F., Barbateskovic, M., Jørgensen, C. K., Hengartner, M. P., Kirsch, I., Gluud, C., & Jakobsen, J. C. (2021). Beneficial and harmful effects of antidepressants versus placebo, ‘active placebo’, or no intervention for adults with major depressive disorder : a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses. Systematic Reviews, 10(154). https://doi.org/10.1186/s13643-021-01705-6
Juul, S. et al. (2021) ‘Beneficial and harmful effects of antidepressants versus placebo, ‘active placebo’, or no intervention for adults with major depressive disorder : a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses’, Systematic Reviews, 10(154). Available at: https://doi.org/10.1186/s13643-021-01705-6.
S. Juul et al., “Beneficial and harmful effects of antidepressants versus placebo, ‘active placebo’, or no intervention for adults with major depressive disorder : a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses,” Systematic Reviews, vol. 10, no. 154, 2021, doi: 10.1186/s13643-021-01705-6.
JUUL, Sophie, Faiza SIDDIQUI, Marija BARBATESKOVIC, Caroline Kamp JØRGENSEN, Michael Pascal HENGARTNER, Irving KIRSCH, Christian GLUUD und Janus Christian JAKOBSEN, 2021. Beneficial and harmful effects of antidepressants versus placebo, ‘active placebo’, or no intervention for adults with major depressive disorder : a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses. Systematic Reviews. 2021. Bd. 10, Nr. 154. DOI 10.1186/s13643-021-01705-6
Juul, Sophie, Faiza Siddiqui, Marija Barbateskovic, Caroline Kamp Jørgensen, Michael Pascal Hengartner, Irving Kirsch, Christian Gluud, and Janus Christian Jakobsen. 2021. “Beneficial and Harmful Effects of Antidepressants versus Placebo, ‘Active Placebo’, or No Intervention for Adults with Major Depressive Disorder : A Protocol for a Systematic Review of Published and Unpublished Data with Meta-Analyses and Trial Sequential Analyses.” Systematic Reviews 10 (154). https://doi.org/10.1186/s13643-021-01705-6.
Juul, Sophie, et al. “Beneficial and Harmful Effects of Antidepressants versus Placebo, ‘Active Placebo’, or No Intervention for Adults with Major Depressive Disorder : A Protocol for a Systematic Review of Published and Unpublished Data with Meta-Analyses and Trial Sequential Analyses.” Systematic Reviews, vol. 10, no. 154, 2021, https://doi.org/10.1186/s13643-021-01705-6.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.